Table 1

Demographics and clinical characteristics of the study population

VariablePsA (N=125)PsC (N=114)p Value
Age (years), mean±SD53.8 (12.1)51.5 (12)0.14
Sex: female60 (48%)48 (42%)0.36
Age at onset psoriasis (years), mean±SD27.3 (14.7)31.7 (17.6)0.04
Age at onset PsA (years), mean±SD39.5 (12.6)
Ethnicity: Caucasian112 (89.6%)94 (82.5%)0.1
Alcohol consumption:
 Daily10 (8%)14 (12.3%)0.007
 Social53 (42.4%)64 (56.1%)
Smoker: ever59 (47.2%)66 (57.9%)0.09
Active joint count, mean±SD4.3 (7.5)
Swollen joint count, mean±SD0.9 (1.9)
Damage joint count, mean±SD6.6 (11.5)
PASI, current, mean±SD2.4 (3.7)5 (5.1)<0.001
PASI, highest, mean±SD7.1 (9.5)6.1 (5.1)0.33
Systolic BP (mm Hg), mean±SD126.4 (16.3)121.6 (16.8)0.02
Diastolic BP (mm Hg), mean±SD77.5 (9.8)77.5 (9.5)0.97
Antihypertensive medications36 (28.8%)28 (24.6%)0.45
Hypertension47 (37.6%)36 (31.6%)0.32
Glucose, mean±SD5.3 (0.9)5.2 (1.3)0.62
Antidiabetes medications11 (8.8%)8 (7%)0.61
Diabetes mellitus15 (12%)9 (7.9%)0.29
Urate (μmol/l), mean±SD336.9 (87)361.6 (90.3)0.04
Total cholesterol (mmol/l), mean±SD5.2 (1.2)4.9 (1.1)0.13
Triglyceride (mmol/l), mean±SD1.5 (1.2)1.4 (0.9)0.51
HDL (mmol/l), mean±SD1.5 (0.7)1.4 (0.5)0.18
LDL (mmol/l), mean±SD3.1 (0.9)2.9 (0.9)0.4
Lipid lowering medications29 (23.2%)20 (17.5%)0.27
BMI (kg/m2), mean±SD29.6 (5.8)28.4 (5.4)0.09
ESR* (mm/h), mean±SD9.9 (11.9)
hsCRP (mg/l), mean±SD10.7 (22.5)4.8 (14.4)0.04
NSAIDs
 Current use79 (63.2%)5 (4.4%)<0.001
 Ever use82 (68.3%)6 (5.5%)<0.001
DMARDs
 Current use73 (58.4%)14 (12.3%)<0.001
 Ever use76 (63.3%)15 (13.5%)<0.001
Anti-TNFα agents
 Current use61 (48.8%)6 (5.3%)<0.001
 Ever use64 (53.3%)6 (5.3%)<0.001
  • *The ESR was only measured in PsA patients.

  • BMI, body mass index; BP, blood pressure; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; NSAID. non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsC, cutaneous psoriasis without arthritis; TNF, tumour necrosis factor.